Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dCcVCfbwoceuqVcZowBJ

April 17, 2012
Sign upForwardArchiveAdvertise
News for Invasive/Interventional Cardiologists

  Top Stories 
  • Md. stenting legislation "an important step," SCAI president says
    Physicians are welcoming legislation in Maryland that establishes a review process to ensure appropriate use of coronary stent placement procedures. The process incorporates established appropriate use criteria. "It is important to note that the bill mandates external peer review. We would have welcomed a bill that mandated both internal and external, but believe this is an important step toward setting a standard for the care of PCI patients," SCAI President Dr. Christopher White said. MedPage Today (free registration) (4/12) LinkedInFacebookTwitterEmail this Story
  • CCI study documents benefits of TAVR in severe aortic stenosis cases
    Surviving patients with severe aortic stenosis show marked improvements from transcatheter aortic valve replacement, according to a study published in Catheterization & Cardiovascular Interventions this month. The study followed 167 high-risk patients with native severe aortic stenosis. Although all-cause mortality was high among the group, researchers said their findings indicate TAVR is "feasible in patients with severe comorbidities and low-flow, low-gradient aortic stenosis." DoctorsLounge.com/HealthDay News (4/13) LinkedInFacebookTwitterEmail this Story
  Policy & Professional News 
  • Drugmakers should have to release complete trial data
    Drugmakers in the U.S. are not required to release full clinical trial reports to researchers or the public, and the FDA does not disclose the data that regulators review in the drug approval process. The result can be use of a drug based on incomplete data published in journal articles, potentially at great public expense, as in the case of Roche Holding's Tamiflu, write research fellow Peter Doshi and epidemiologist Tom Jefferson. The European Medicines Agency intends to release clinical study data after regulators review a manufacturer's application, and the FDA should follow suit, the scientists argue. The New York Times (tiered subscription model) (4/10) LinkedInFacebookTwitterEmail this Story
 
  • Senator advocates finding common ground between FDA, industry
    The FDA and the medtech industry can work together to speed the device approval process without putting patient safety at risk, Minnesota Sen. Al Franken said during an interview at a conference in Minnesota. The key is to look for common ground between the two groups, a goal that a Regulatory Sciences Partnership is designed to achieve, he said. "The longer things take to get to market, it makes the thing not cost-effective to do in the first place," said Franken. Star Tribune (Minneapolis-St. Paul, Minn.)/Patent Pending blog (4/12) LinkedInFacebookTwitterEmail this Story
  Medical Developments 
  • Engineers create device to aid angioplasty procedures
    Biomedical engineers have created a new device that combines embolic protection and angioplasty balloon technologies to help treat narrowed or blocked blood vessels. The team at the University of Limerick hopes the device will improve angioplasty success rates. "In practice, this means the angioplasty balloon can be left in a full inflated state in the artery for a longer period of time than is currently possible," said principal investigator Michael Walsh. Silicon Republic (Ireland) (4/11) LinkedInFacebookTwitterEmail this Story
  • Electrocardiogram spots risk of cardiac events among seniors
    Electrocardiogram abnormalities were linked to a greater risk of heart attack and other cardiac events among seniors ages 70 to 79, according to a study in the Journal of the American Medical Association. However, researchers said more study is needed to determine whether the small benefit offered by the test warrants its inclusion in screening asymptomatic patients. The Wall Street Journal (4/10), HealthDay News (4/10) LinkedInFacebookTwitterEmail this Story
  • Study to assess use of stem cells after heart attack
    Researchers are conducting trials to examine how stem cells derived from pelvic bone marrow can be used to restore tissue following a heart attack. "The thought is the body may use itself to heal itself. Because stem cells are immature cells, they have the potential to develop into new blood vessels and preserve cardiac muscle cells," says interventional cardiologist and lead researcher Dr. Vijaykumar Kasi. Medical News Today (4/14) LinkedInFacebookTwitterEmail this Story
  • Other News
  SCAI News 
  • SCAI-QIT AUC and Guidelines App to be unveiled at SCAI 2012
    Interventional cardiologists will soon have access to a tool that puts several appropriate use criteria (AUC) and guidelines at their fingertips. To be unveiled during the SCAI Quality Improvement Toolkit (SCAI-QIT) Session at SCAI 2012 on Thursday, May 10, the SCAI-QIT AUC and Guidelines App will be a handy alternative to carrying these print documents in a coat pocket. The launch will include the recently updated AUC for Coronary Revascularization, and plans for expansion are already under way. Find out more. LinkedInFacebookTwitterEmail this Story
Learn more about SCAI ->Join SCAI  |  SCAI 2012  |  SCAI Education & Meetings  |  SCAI e-Learning
Advocacy Update  |  Information for Your Patients

  SmartQuote 
Man cannot discover new oceans unless he has the courage to lose sight of the shore."
--André Gide,
French author


LinkedInFacebookTwitterEmail this Story

 
The news summaries appearing in SCAI SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. SCAI is not responsible for the content of sites external to SCAI, nor do reports in SCAI SmartBrief constitute the official opinion of SCAI.

The SCAI SmartBrief news roundup is provided as a timely update for SCAI members and other healthcare professionals. Links to articles are provided for readers' convenience and may be of use in discussions with patients or colleagues. Questions and comments about SCAI SmartBrief may be directed to SmartBrief at scai@smartbrief.com.
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Aaron Kern (202) 407-7866
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent SCAI SmartBrief Issues:   Lead Editor:  Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information